Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.2.617

Early Efficacy of Taxotere and Cisplatin Chemo-Radiotherapy for Advanced Cervical Cancer  

Ke, Qing-Hua (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Zhou, Shi-Qiong (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Du, Wei (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Lei, Yong (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Huang, Min (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Luo, Fei (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Yang, Ji-Yuan (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.2, 2012 , pp. 617-619 More about this Journal
Abstract
The aim of this study was to investigate the early outcome of the taxotere and cisplatin chemoradiotherapy for advanced cervical cancer. Fifty-six cases (FIGO II b to IVa) were divided randomly into two groups: radiotherapy alone (28 cases) and radiation plus chemotherapy (TP) group. There was no difference in radiotherapy between the two groups. The RT+C cases who received TP regimen during the radiation, and DDP once weekly injection of vain, according to 20$mg/m^2$ and taxotere once weekly iv according to 35 $mg/m^2$. These regimens were given for 4~5weeks, and some medicines to control vomiting were available for the RT+C cases. The two groups received an oral medicine MA 160mg every day during the treatment. Regarding early outcome, the complete remission rate was 64.3% and partial remission rate was 35.7% in RT+C. The complete remission rate was 32.1% and partial remission rate was 39.3% in RT. The total response rate and complete remission in the RT+C group were higher than that in the RT group. We conclude that taxotere and cisplatin chemoradiotherapy can improve the early outcome of the advanced cervical cancer, the adverse effects being endurable.
Keywords
Cervical cancer; taxotere and cisplatin; chemoradiotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bai XK, Zhao Z (2001). The clinic investigation of the effectiveness of medicine MA on the survival condition of cancer patients in chemotherapy period. Shanxi Oncol Med, 9, 161-2.
2 Dubay RA, Rose PG, O'Malley DM, et al (2004). Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol, 94, 121-4.   DOI
3 Duenas-Gonzalez A, Zarba JJ, Patel F, et al (2011). Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol, 29, 1678-85.   DOI
4 Eifel PJ, Winter K, Morris M, et al (2004). Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high- risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol, 22, 872-80.   DOI   ScienceOn
5 Green JA, Kirwan JM, Tierney JF, et al (2001). Survival and recurrence after concom itant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet, 358, 781-6.   DOI   ScienceOn
6 Higgins RV, Naumann WR, Hall JB, et al (2003). Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol, 89, 499-503.   DOI
7 Lorvidhaya V, Chitapanarux I, Sangruchi S, et al (2003). Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervical: a randomized trial. Int J Radiat Oncol Biol Phys, 55, 1226-32.   DOI
8 Lu P, Liang QD, Zheng QQ (2003). Influence of clinical and pathologic parameters on prognosis of cervical carcinoma in China. Chinese-German J Clin Oncol, 2, 163-5.   DOI
9 Morris M, Eifel PJ, Lu J, et al (1999). Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high- risk cervical cancer. N Engl J Med, 340, 1137-43.   DOI   ScienceOn
10 Peters WA, Liu PY, Barrett RJ, et al (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervical. J Clin Oncol, 18, 1606-13.   DOI
11 Pignata S, Frezza P, Tramontana S, et al (2000). Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann Oncol, 11, 455-9.   DOI   ScienceOn
12 Rose PG, Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 25, 2804-10.   DOI   ScienceOn
13 Rose PG, Bundy BN, Watkins EB, et al (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med, 340, 1144-53.   DOI   ScienceOn
14 Sun Y, Zhou JC (2002). 4 Edition. Beijing: People's Medical Publishing House. Manual of medical oncology, 106-418.
15 Thomas GM (1999). Improved treatment for cervical cancerconcurrent chemotherapy and radiotherapy. N Engl J Med, 340, 1198-200.   DOI   ScienceOn
16 Wang HQ (2002). Shenyang: Lianing Sience and Tchnology Publishing House. Malignant tumor chemotherapy regimens norms, 16.